SCHEMBL4866856

SCHEMBL4866856

NC1=C(Cl)C[CH]C=C1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15228369 0.72
Ethane SCHEMBL28805784 0.68
SCHEMBL13539370 0.55
SCHEMBL4564071 0.53
SCHEMBL4781154 0.50
SCHEMBL5462925 0.50
SCHEMBL11809662 0.48
SCHEMBL11700699 0.46 GAA (0.33)
SCHEMBL5074259 0.46
SCHEMBL320324 0.46

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3331848-A1 A PROCESS FOR PREPARING AGONIST Vamsi Labs Ltd. (IN) 2018-06-13 EP claimed
WO-2017021982-A1 A PROCESS FOR PREPARING β AGONIST VAMSI LABS LTD. (IN) 2017-02-09 WO claimed
EP-3331848-A1 A PROCESS FOR PREPARING AGONIST Vamsi Labs Ltd. (IN) 2018-06-13 EP disclosed
WO-2017021982-A1 A PROCESS FOR PREPARING β AGONIST VAMSI LABS LTD. (IN) 2017-02-09 WO disclosed
US-20080269344-A1 Beta2-Adrenergic Receptor Agonists THERAVANCE BIOPHARMA R&D IP, LLC 2008-10-30 US disclosed
US-7427639-B2 β2-adrenergic receptor agonists THERAVANCE, INC. (US) 2008-09-23 US disclosed
US-20070179179-A1 Beta2-adrenergic receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC 2007-08-02 US disclosed
US-7217738-B2 β2-adrenergic receptor agonists THERAVANCE, INC. (US) 2007-05-15 US disclosed
US-20050261338-A1 Beta2-adrenergic receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC 2005-11-24 US disclosed
US-6916961-B2 β2-adrenergic receptor agonists THERAVANCE, INC. (US) 2005-07-12 US disclosed
US-6576793-B1 β2-adrenergic receptor agonists THERAVANCE, INC. 2003-06-10 US disclosed